ARA-C AND AMSA FOR TREATMENT OF RELAPSED AND REFRACTORY ACUTE MYELOID-LEUKEMIA

被引：0
|
作者：
JAGER, U
LECHNER, K
SCHWARZINGER, I
BETTELHEIM, P
BOGNAR, H
GEISSLER, K
HAAS, O
HINTERBERGER, W
KOS, M
LEITHA, T
NEUMANN, E
PANZER, S
POLLAK, C
机构：
[1] VIENNA UNIV,DEPT MED 1,A-1010 VIENNA,AUSTRIA
[2] ST ANNA CHILDRENS HOSP,VIENNA,AUSTRIA
来源：
BLUT | 1986年 / 53卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：145 / 145
页数：1
相关论文
共 50 条
  • [31] A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia
    Karanes, C
    Kopecky, KJ
    Head, DR
    Grever, MR
    Hynes, HE
    Kraut, EH
    Vial, RH
    Lichtin, A
    Nand, S
    Samlowski, WE
    Appelbaum, FR
    LEUKEMIA RESEARCH, 1999, 23 (09) : 787 - 794
  • [32] A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia
    Rosen, PJ
    Rankin, C
    Head, DR
    Boldt, DH
    Luthardt, FW
    Norwood, T
    Pugh, RP
    Karanes, C
    Appelbaum, FR
    LEUKEMIA RESEARCH, 2000, 24 (03) : 183 - 187
  • [33] Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
    Richard L Momparler
    Experimental Hematology & Oncology, 2 (1)
  • [34] Irinotecan (CPT-11) and cytarabine (Ara-C) in refractory acute myeloid leukemia (AML).
    Minderman, H
    O'Loughlin, KL
    Thomas, KJ
    Pixley, LA
    Wetzler, M
    Slack, JL
    Baer, MR
    LEUKEMIA, 2001, 15 (03) : 509 - 509
  • [35] Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
    Momparler, Richard L.
    EXPERIMENTAL HEMATOLGY & ONCOLOGY, 2013, 2
  • [36] LOW-DOSES OF ARA-C IN CHRONIC MYELOID-LEUKEMIA IN BLASTIC TRANSFORMATION
    DIRAIMONDO, F
    GUGLIELMO, P
    MILONE, G
    CACCIOLA, E
    GIUSTOLISI, R
    HAEMATOLOGICA, 1985, 70 (03) : 275 - 276
  • [37] Treatment for Relapsed/Refractory Acute Myeloid Leukemia
    Thol, Felicitas
    Heuser, Michael
    HEMASPHERE, 2021, 5 (06): : E572
  • [38] INVIVO GROWTH AND ARA-C PHARMACOLOGICAL DETERMINANTS OF CLINICAL-RESPONSE IN ACUTE MYELOID-LEUKEMIA (AML)
    KARP, JE
    DONEHOWER, RC
    DOLE, GB
    ENTERLINE, J
    BURKE, PJ
    CELL AND TISSUE KINETICS, 1988, 21 (01): : 61 - 62
  • [39] Treatment of Relapsed/Refractory Acute Myeloid Leukemia
    Bose, Prithviraj
    Vachhani, Pankit
    Cortes, Jorge E.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (03)
  • [40] Treatment of Relapsed/Refractory Acute Myeloid Leukemia
    Prithviraj Bose
    Pankit Vachhani
    Jorge E. Cortes
    Current Treatment Options in Oncology, 2017, 18
12345